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Complementation of Reduced Survival, Hypotension, and Renal Abnormalities
in Angiotensinogen-deficient Mice by the Human Renin and Human 
Angiotensinogen Genes
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The aim of this study was to determine whether elements of
the human renin-angiotensin system (RAS) could function-
ally replace elements of the mouse RAS by complementing
the reduced survival and renal abnormalities observed in
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mice, including thickened arterial walls, severe fibrosis,
lymphocytic infiltration, and atrophied parenchyma, was














 mice. Direct arterial
blood pressure recordings in conscious freely moving mice









































































































These studies establish that the human renin and angio-
tensinogen genes can functionally replace the mouse angio-
tensinogen gene, and provides proof in principle that we can
examine the regulation of elements of the human RAS and
test the significance of human RAS gene variants by a com-



























Human essential hypertension, or high blood pressure of un-
defined etiology, is an abnormality influenced by both poly-
genic and environmental factors. Compelling evidence in sup-
port of a genetic contribution to human essential hypertension
stems from genetic epidemiology studies of twins and adopted
siblings (1, 2). Technical advances in examining polygenic dis-
eases in humans over the past few years has prompted numer-
ous studies of the underlying genetic causes of essential hyper-
tension. Except for the genes that cause rare Mendelian forms
of hypertension, such as glucocorticoid remediable aldoster-
onism (chimeric duplication of 11 beta-hydroxylase and aldo-









units of renal-epithelial sodium channel) (4), the strongest
evidence implicating a gene as the cause of human essential




) gene (5). An-









the successive actions of renin and angiotensin converting en-
zyme (ACE). Ang-II is a potent regulator of vascular hemody-
namics and a determinant of cardiovascular homeostasis; in-
hibitors of Ang-II production (ACE inhibitors) or action
(Ang-II receptor antagonists) are effective antihypertensive
agents in many patients.
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hibit high plasma Ang-II levels, altered baroreflex activity, and




) plasma angiotensinogen and
arterial blood pressure vary proportionally with the number of








) gene in gene-tar-





from studies implicating variants of the gene in the genetic basis
of preeclampsia, a disorder characterized by hypertension, pro-
teinuria, and edema after the 20th wk of pregnancy (12, 13).
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The renin-angiotensin system (RAS) may also play an im-











 mice exhibit hypotension and reduced sur-











 mice and occasional adult survivors has
demonstrated marked renal abnormalities consisting of severe
renal vascular hypertrophy, cortical thinning, severe focal fi-
brosis, tubular atrophy, and chronic inflammation (11, 14, 15).








 genes as tools for studying the regulation of the
human RAS and its role in blood pressure regulation and or-
gan function. Driven by their respective endogenous promot-
ers, each of these transgenes exhibits normal tissue- and cell-
specific expression and are appropriately regulated (16–19).
Although the enzymatic reaction between renin and angio-
tensinogen is species specific (i.e., human renin cannot cleave
mouse angiotensinogen, and mouse renin cannot cleave hu-
man angiotensinogen), the Ang-I and Ang-II peptides are
identical in rodents and humans (20). We therefore proposed
that elements of the human RAS may be able to complement
the lethal phenotype observed in mice homozygous for a tar-




 gene. The aim of this study was













cient mice in order to determine whether those elements of the
human RAS would rescue the reduced survival and correct the





cient mice. The resulting mice should also provide a model to









without the confounding influence of their endogenous coun-
terparts, and to assess the feasibility of examining the physio-




 variants identified in human




Experimental mice and husbandry. The generation of mice having a
targeted disruption of the mAgt gene has been described previously
(11); the mAgt1/2 mice used for the breeding scheme illustrated in
Fig. 1 were maintained by backcross breeding to C57BL/6J. The
methods used for the generation of mice containing both the HREN
and HAGT transgenes have been described previously (9, 16, 18). In
addition, the tissue- and cell-specific expression exhibited by both
transgenes in single and double transgenic mice has been previously
described in detail (9, 16–18). The HAGT transgene segregates as an
autosomal trait while the HREN transgene is linked to the X-chro-
mosome (16, 18).
Pups were weaned at 21 d, at which time tail biopsies were taken
for genotyping. To assess the relative survival of pups of the various
genotypes, all cages were monitored carefully from birth for dead
mice, which were retrieved for sampling and genotyping. After wean-
ing, cages continued to be monitored carefully for deaths. All mice
were fed standard mouse chow (LM-485; Teklad Premier Laboratory
Diets, Madison, WI) and water ad libitum. Care of the mice used in
the experiments met or exceeded the standards set forth by the Na-
tional Institutes of Health in their Guidelines for the Care and Use of
Experimental Animals. All procedures were approved by the Univer-
sity Animal Care and Use Committee at the University of Iowa.
Genotyping. Genomic DNA was purified from tail biopsy sam-
ples as previously described (21, 22). The mAgt locus was genotyped
by Southern blot analysis as previously described (11). Briefly, XbaI-
digested tail DNA was separated on 0.8% agarose gels, transferred to
nitrocellulose membranes, and hybridized with a radioactively la-
beled DNA probe that spans the area of the targeted disruption, exon
2. HREN and HAGT oligonucleotide primer sets specific for human
sequences were used to assay for the presence or absence of the
transgenes as described previously (9). This PCR-based assay does
not allow us to distinguish between mice that are either heterozygous
or homozygous for the HREN or HAGT transgenes. Since the level
of plasma human angiotensinogen is already in high excess, it is un-
likely that the presence of additional copies of the transgene will have
any effects on the blood pressure of those mice (18). Moreover, since
the HREN gene is linked to the X-chromosome (16, 17), all HREN
transgenic males will be hemizygous for the transgene. Although fe-
male mice may differ with respect to the HREN transgene copy num-
ber, the absence of a difference in blood pressure between males and
females in any experimental group, the low variance in blood pres-
sure measurements within individual groups and the high correlation
between mAgt gene copy number in the RA1 group (see Results), ar-
gues against a transgene copy number effect on blood pressure.
Blood pressure measurement. 3 d before blood pressure record-
ing, mice were weighed, anesthetized with ketamine (120 mg/kg, i.p.)
and acepromazine maleate (12 mg/kg, i.p.), and surgically instru-
mented with a left common carotid artery catheter (Microrenathane;
Braintree Science Inc., Braintree, MA) (0.04 in outer diameter 3
0.025 in inner diameter, drawn over heat) for the measurement of
pulsatile and mean arterial blood pressure (MAP) and heart rate
(HR, pulse pressure-triggered cardiotachometer). The catheter was
tunneled subcutaneously, exteriorized between the scapulae, and the
free end was led through a larger piece of protective tubing (PE 160)
that was flanged at one end. The scapular incision was closed around
the flanged end of the tubing to secure the catheter to this region.
The neck wounds were also closed (silk 6-0). Catheters were filled
and flushed daily with a sterile dilute heparinized saline (25 U/ml).
After a 3-d recovery period, mice remained in their home cages and
were connected to a Beckman Dynograph-coupled pressure trans-
ducer (Cobe Laboratories, Inc., Lakewood, CO) for the recording of
cardiovascular parameters. The mice were allowed a 60-min stabiliza-
tion period after connection to the recording equipment. Mice were
allowed to move freely. Blood pressure and HR were recorded con-
tinuously for 90–120 min and the data was calculated from the mean
of five MAP and HR samplings for each animal during this time.
Organ collection and renal histology. After blood pressure re-
cording, mice were killed by CO2 asphyxiation. A midline abdominal
incision was made and the kidneys were removed, rinsed in sterile sa-
line, and fixed in 10% neutral-buffered formalin. The kidneys were
embedded in paraffin, sectioned (5 mm coronal and saggital), and
stained with hematoxylin and eosin. Arterial wall thickness, cortical
thickness, number and size of cortical tubules, presence of interstitial
inflammatory cells, and glomerular density were examined in the kid-
neys of a minimum of two different mice from each of the genotype
Figure 1. Breeding 
scheme. A schematic of 
the breeding strategy 
used to generate mice 
containing combina-
tions of the HREN and 
HAGT transgenes and 
gene-targeted disrup-
tions of the mAgt gene. 
Male mice are repre-
sented by a square, and females by a circle. Brother/sister intercrosses 
of double transgenic mAgt1/2 mice yielded 139 offspring that were 
analyzed for genotypes. A subset of each genotypic group was ana-
lyzed for blood pressures and kidney histologies. The individual 
HREN and HAGT transgenics used to generate the double trans-
genic mice in the first breeding are heterozygous for each of the 
transgenes. The HREN transgene is present on the X-chromosome 
and exhibits a sex-linked mode of inheritance. The HAGT gene is au-
tosomal.
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groups: RA2 mAgt2/2, RA1 mAgt2/2, RA2 mAgt1/1, RA1
mAgt1/1, and RA2 mAgt1/2. Investigators examining the histolog-
ical samples were “blind” to the genotypes.
Statistical analysis. Blood pressure is expressed as mean6SEM.
The SEM was determined by the formula (EMS/n)1/2 where EMS is
the error mean square term from ANOVA and n is the number of an-
imals per group (23). The data were analyzed by one-way ANOVA
(23) followed by Student’s modified t test with Bonferroni correction
for multiple comparisons between means (24) using the modified er-
ror mean square term from the ANOVA. Genotype frequencies were
compared with expected Mendelian proportions by chi-square (x2)
(25). Regression analysis was used to determine the relationship be-
tween mAgt gene copy number and MAP (26).
Results
Experimental strategy. The long term goal of the studies of
which the present experiments are a part is to develop animal
models to examine the physiological importance of candidate
AGT gene variants reported to be associated with increased
plasma angiotensinogen and high blood pressure in humans (5,
13). We here use a combination of transgenic and gene-target-
ing techniques to functionally replace the mouse renin-angio-
tensin system with its human equivalent. We have previously
demonstrated that transgenic mice containing the HREN and
HAGT genes express the human genes appropriately (16–18)
and that their combined expression results in chronic hyper-
tension (9). We have also observed that the expression of en-
dogenous renin mRNA was modulated in the hypertensive
mice in response to increased blood pressure and/or Ang-II
levels (19). We therefore wanted to determine if the HREN
and HAGT genes could functionally replace the endogenous
mouse renin and angiotensinogen genes in order to ensure that
any subtle effects on blood pressure of subsequent HAGT
gene variants would not be masked by compensatory changes
in the endogenous system. Gene-targeted mice deficient in
mAgt (11, 14, 15), ACE (27, 28), Ang-II type 1A receptor (29,
30), and Ang-II type II receptor (31, 32) have been developed.
We chose the Agt deficient mice because the angiotensinogen
protein (AGT) provides the only known Ang-II precursor and
that its deletion should functionally cripple the system. This
would allow the mouse ACE and Ang-II receptors to become
dependent upon HREN and HAGT and function as a human/
mouse chimeric RAS.
Breeding and genotyping. Fig. 1 shows the breeding scheme
used to generate transgenic mice containing both the HREN
and HAGT genes on mAgt2/2 background. In the first round
of breeding, heterozygous male HAGT mice (A1/A2) were
bred with heterozygous female HREN mice (R1/R2) and the
double transgenics (R1/A1) were identified by PCR and se-
lected for further breeding. In the second generation, male
mAgt1/- mice were bred with female double transgenic mice
from the first breeding. Brother and sister offspring containing
both human transgenes, as identified by PCR, and also het-
erozygous for the mAgt deletion, as identified by Southern
blot analysis, were interbred for the third round of breeding.
This strategy yielded offspring with different combinations of
the human transgenes and targeted mAgt alleles that were dis-
tinguished by PCR and Southern blot analysis as illustrated in
Fig. 2. Our previous data showed that single transgenic mice
(R1/A2, R2/A1) are phenotypically indistinguishable from
nontransgenic mice (R2/A2) with respect to plasma renin ac-
tivity, plasma Ang-II levels, and blood pressure (9). Conse-
quently, there are only two combinations of HREN/HAGT
transgenes that need to be distinguished: double transgenic an-
imals having both HREN and HAGT transgenes, which we
will designate RA1, and animals having no or one transgene,
which we will designate RA2. Thus, when combined with
three possible mAgt genotypes, there are six classes of animals.
Genotype data were collected on 139 live born offspring
(71 males and 68 females) from 19 litters of the R1/A1 mAgt1/2
intercross. Each mouse was scored as either positive or nega-
tive for each human transgene and either as wild type (1/1),
heterozygous (1/2), or homozygous (2/2) for the gene-tar-
geted deletion at the mAgt locus. A summary of all genotype
data from this population is shown in Table I.
Complementation of the lethal phenotype. The breeding strat-
egy we employed yielded a large number of double transgenic
mice (RA1, n 5 69). We were therefore able to obtain a sub-
Figure 2. Sample genotype data. (A) A 
representative Southern blot of Xba1-
digested tail DNA from offspring of the 
breeding shown in Fig. 1 is shown. Hy-
bridizing bands corresponding to the wild-
type (mAgt1) and targeted (mAgt2) loci 
are indicated. (B) A representative gel of 
tail DNA PCR reactions using primers 
specific for the HREN and HAGT genes 
is shown. Positions of the PCR products 
are indicated. 1, transgene positive;
2, transgene negative. The deduced geno-
type for each animal is shown at the top of 
each lane.
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stantial number of animals in which survival could be corre-
lated with RA and mAgt genotypes. A summary of the mAgt
locus genotype in the two populations, RA1 (double transgen-
ics) and RA2 (nontransgenic or single transgenic), that sur-
vived to 3 mo of age is shown in Table II.
The highest mortality rate (70% at 3 mo of age and 80% at
5 mo of age) was evident in mAgt2/2 mice that lacked one or
both human transgenes (RA2). The loss of RA2 mAgt2/2
mice was highly significant (P , 0.001 by x2). Of a total of 131
offspring (139 minus 8 deaths), only three RA2 mAgt2/2
mice survived postweaning and only two survived beyond five
mo of age. In contrast, in the RA1 group we observed the ap-
propriate proportions of animals that were wild type, het-
erozygous, and homozygous at the mAgt locus as predicted by
Mendelian segregation (P . 0.05 by x2 ). Indeed, all RA1
mAgt2/2 mice (17 total, 9 males and 8 females) survived until
they were killed after blood pressure was recorded (5–9 mo of
age). Similarly, no significant difference in survival was evident
among mAgt1/1 or mAgt1/2 mice, regardless of the human
transgene genotypes. These data clearly demonstrate that the
presence of both human transgenes is necessary and sufficient
to rescue the lethality caused by the mAgt deletion.
To determine whether homozygous mAgt2/2 animals
were born at appropriate Mendelian proportions or were dy-
ing in utero, we performed two test breedings between RA2
mAgt1/2 mice. Offspring were continuously observed over a
3-wk period to ensure collection of their remains after animals
died. From a total of 16 offspring, 3 were mAgt1/1, 7 were
mAgt1/2, and 6 were mAgt2/2 (3:7:6 vs. 4:8:4, P . 0.05 by
x2). However, all the mAgt2/2 mice died before weaning,
while all remaining mice survived to adulthood.
Complementation of renal pathology. Examination of kid-
neys from the two surviving adult RA2 mAgt2/2 mice
Table I. Genotype Summary from all Offspring
mAgt genotype
HREN/HAGT genotype
R2/A2 R1/A2 R2/A1 R1/A1
1/1 4 10 5 18
1/2 17 19 5 34
2/2 4 5 1 17
Figure 3. Kidney histopathology. Representative examples of histology of kidneys from an adult wild type (A and B), an RA2 mAgt2/2 (C and 
D), and an RA1 mAgt2/2 (E and F). A, C, and E are of the renal cortex. Severe lymphocytic infiltration is evident in a mAgt2/2 mouse (C) but 
not in an RA1 mAgt2/2 mouse (E). B, D, and F show a comparison of interlobular arteries. Marked arterial wall thickening is evident in the 
mAgt2/2 mouse (D), but normal arterial wall thickness is evident in the wild type (B) and RA1 mAgt2/2 (F).





RA1 (n 5 68) RA2 (n 5 63)
Expected Observed Percent Expected Observed Percent
1/1 17 17 25 16 19 30
1/2 34 34 50 31 41 65
2/2 17 17 25 16 3* 5*
*P , 0.05 by x2 for observed vs. expected.
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showed marked renal pathology. Although not significantly
reduced in weight, kidneys from these mutants had thinned
cortices surrounding severely atrophied medullary regions.
Moderate to severe medial thickening of arterial walls in the
RA2 mAgt2/2 mice, with near complete occlusion of the lu-
men in many of the arteries (Fig. 3 D), was observed routinely.
Similar dysplasia was evident in the kidneys from RA2
mAgt2/2 mice found dead in their cages. In addition to the ar-
terial thickening and occlusion, renal lesions characterized by
areas of abnormal parenchyma consisting of numerous cystic
spaces around glomeruli, dilated and/or atrophied tubules, and
multiple areas of fibrosis often associated with dense lympho-
cytic infiltrates were commonly observed (Fig. 3 C). The num-
bers and size of glomeruli were generally reduced compared
with kidneys from wild-type controls, although glomeruli out-
side the hypoplastic zone were frequently enlarged and more
cellular. In contrast, kidneys from the RA1 mAgt2/2 mice
(Fig. 3, E and F) (n 5 7) were generally indistinguishable from
wild-type controls (Fig. 3, A and B), although some very mild
and rare focal regions of fibrosis were detected. In addition,
some of the larger arteries in one RA1 mouse had mild thick-
ening of the media. Glomeruli, tubules, and the interstitium
appeared normal in these mice. There were no abnormalities
observed in kidneys from RA2 mAgt1/2 or RA1 mAgt1/2
mice. Consistent with severe hypertension, the RA1 mAgt1/1
mice exhibited thrombotic glomeruli, vascular necrosis, and ar-
teritis.
Physiological characterization of the mice. Blood pressure
was measured in representatives of each genotypic group using
an indwelling carotid arterial catheter in mice that were con-
scious and freely moving. A typical pulse pressure tracing and
a summary of MAP in each group is shown in Fig. 4. As we
have previously demonstrated (9), RA1 mAgt1/1 mice are
chronically hypertensive (17463 mmHg) compared with ei-
ther single- or nontransgenic control mice (10562 mmHg).
Both RA1 mAgt2/2 (13263 mmHg) and RA1 mAgt1/2
(14664 mmHg) mice had blood pressures that were intermedi-
ate between RA2 mAgt1/1 and RA1 mAgt1/1 animals.
There was a strong relationship between mAgt copy number
and blood pressure in the RA1 population (r 5 0.973, P ,
0.001, Fig. 4 C). In contrast, two surviving RA2 mAgt2/2
adult mice were hypotensive (8661 mmHg) compared with
wild-type controls (10562 mmHg) (two-sample t test, P ,
0.05). Heart rate did not differ among groups (data not shown,
P . 0.05 for all comparisons), and there was no correlation be-
tween blood pressure and the age or sex of the mice used in these
studies (P . 0.05 for all comparisons in mice 5–8 mo of age).
Discussion
Experimental strategy and rationale. The molecular genetic evi-
dence that variants of the human AGT gene are linked to hy-
pertension and pregnancy-induced hypertension (5, 12, 13)
motivated our long term goal of developing appropriate model
systems for experimentally testing the functional consequences
of such alleles. In the present work, we generated mice that
were transgenic for both HAGT and HREN, but lacked mAgt.
This experimental approach is made possible by the strict spe-
cies specificity of the enzymatic reaction between renin and
angiotensinogen, which leaves endogenous mouse renin un-
able to cleave AGT, together with the evolutionary conserva-
tion of the Ang-I and Ang-II peptides, which allows the endog-
enous ACE and Ang-II receptors to function normally.
Therefore, in this system we expected that both HAGT and
HREN would be required to restore Ang-I generation, but
that the human homologs of the ACE and Ang-II receptor
genes would not be necessary. We have previously demon-
strated that the HAGT and HREN genes are each expressed
in an appropriate tissue- and cell-specific manner (16–18) and
that both genes are expressed in double transgenic mice (9).
These expectations are validated by our demonstration that a
chimeric human/mouse RAS is functional as judged by our find-
ing that transfer of the HREN and HAGT genes corrects the re-
duced survival and renal lesions observed in mAgt2/2 mice.
The renin-angiotensin system in development. The finding
that Agt-deficient mice exhibit severe renal lesions shortly af-
ter birth suggests that the RAS may play a critical role in the
continued development of the kidney during neonatal life. The
kidney is among several tissues in which all components of the
RAS cascade are expressed (33). Therefore, in addition to the
local hemodynamic and volume homeostatic effects regulated
by the intrarenal RAS, it remains possible that the system may
also be an important regulator of kidney growth and develop-
ment. The potent effects of ACE inhibitors on regression of
ventricular hypertrophy, aortic medial thickness, and myocar-
dial infarction–induced remodeling (34), along with in vitro ev-
idence that Ang-II activates factors associated with growth in a
variety of cardiovascular cell types including cardiac myocytes
(35), endothelial cells (36), and vascular smooth muscle cells
(37) all point to a potential role of the RAS in regulating car-
diovascular cell structure and growth. Similarly, pharmacologi-
cal studies showing that AT-1 receptor blockade (38) or ACE
inhibition (39) in neonates results in a reduction in the number
and size of renal afferent arterioles and glomeruli has led to
Figure 4. Blood pressure analysis. (A) A typical blood pressure re-
cording in a 26 g conscious freely moving mouse using a carotid arte-
rial catheter. Arrows 1, 2, and 3 denote chart recorder speeds 0.5, 
0.025, and 2.5 mm/s, respectively. (B) A summary of basal MAP in 
each group of mice. The genotype of each group is shown. Numbers 
of animals in each group are shown on the bars. Data are expressed 
as mean6SEM. *P , 0.05, RA2 mAgt1/1 vs. all RA1 groups, one-
way ANOVA; ‡P , 0.05 RA2 mAgt1/1 vs. RA2 mAgt2/2, two-
sample t test; †P , 0.05, RA1 mAgt1/1 vs. all other groups. (C) The 
relationship between MAP and mAgt gene copy number in the RA1 
group is shown (r 5 0.973, P , 0.001).
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proposals that the RAS mediates normal embryonic and post-
natal kidney development. However, the finding of severe
arterial wall thickening and hyperplasia in the kidneys of
mAgt2/2 mice is unexpected given that Ang-II is a growth-
promoting factor. One possible explanation is that absence of
AGT and therefore Ang-II may lead to activation of some
other growth factors. Indeed, Niimura et al. (14) report an up-
regulation of platelet-derived growth factor and transforming
growth factor mRNA in thickened arteries of mAgt-deficient
mice. Moreover, recent studies suggesting a role of Ang-II
type 2 receptors (AT-2) in apoptosis suggests that the thick-
ened arterial walls could be in part mediated by inappropriate
smooth muscle cell replication (40). Because the renal pheno-
type was not improved in mAgt2/2 mice bearing the HAGT
gene alone, our findings suggest that it is the loss of Ang-II,
rather than AGT per se, that is causal to the renal pathology
observed in the mAgt2/2. Nevertheless, we cannot formally
rule out that des-angiotensin (angiotensinogen without the
Ang-II peptide) mediates these effects by an undiscovered
mechanism. The need for further studies to delineate the pre-
cise mechanisms by which Ang-II participates in growth and
development of the kidney is underscored by the finding of an
essentially identical form of abnormal renal morphology in
ACE-deficient mice (27), but not in AT-1A or AT-2 receptor-
deficient mice (29, 31).
Genotypic variation in blood pressure and implications for
future studies. Jeunemaitre et al. (5) found that variants in the
AGT gene correlated with small but significant changes in
plasma AGT and elevated blood pressure. To determine
whether modest increases and decreases in plasma AGT alter
blood pressure, Smithies and Kim (10) studied the effects of
stepwise increases in the mAgt gene copy number from one to
four and found a significant increase in both plasma AGT
(from 35% of normal in one-copy mice to 145% of normal in
four-copy mice) and blood pressure (z 8 mmHg per gene
copy). Our studies also demonstrate that blood pressure in the
double transgenic mice is proportional to mAgt gene copy
number. Surprisingly, the effect is considerably greater (z 21
mmHg per mAgt copy) in the double transgenics. These data
show that the hypertension observed in the double transgenics
that are wild type at the mAgt locus is due to the additive effect
of the endogenous and the human renin-angiotensinogen
genes. The contribution of the human genes is quantitatively
greater than the contribution of the mouse genes in this model
since blood pressure in RA1 mAgt1/1 is z 42 mmHg higher
than RA1 mAgt2/2 mice, but 69 mmHg higher than RA2
mAgt1/1.
The proportionality of mAgt copy number and blood pres-
sure in the RA1 mice was initially surprising since we previ-
ously reported that mouse renin mRNA is downregulated in
the kidney of the double transgenics (19). In normal mice,
however, plasma renin is high whereas plasma AGT is low (41,
42). Evidently, even when renin mRNA is significantly down-
regulated, sufficient plasma renin remains so that as plasma
AGT increases with increasing mAgt gene copy number,
mAgt-derived Ang-II in excess of that produced from human
AGT causes an increase in blood pressure. The surprisingly
large effect may indicate that the homeostatic mechanisms in
the RA1 mice are stressed to the point that compensation for
variations in mAGT levels are less effective than in RA2 mice.
We expect that the use of a combined transgenic/gene-tar-
geted mouse strategy of the type illustrated here will allow us
to functionally examine the role of human AGT variants in
causing hypertension. The above data emphasize the value of
using mAgt2/2 mice for determining the contribution of hu-
man RAS gene variants to blood pressure differences, since in
these animals homeostatic changes in mouse renin synthesis
will not affect Ang-II levels. This avoids many of the complica-
tions that altered mouse RAS activity can introduce when
comparing the blood pressure in animals containing a series of
variants. We are therefore using a novel gene targeting ap-
proach to transfer various haplotypes of the HAGT gene to a
selectable locus where single-copy identical-site insertions can
be accomplished (43). This will eliminate copy-number and
position effects on expression that result from random integra-
tion of transgenes into the genome (43–46) and consequently
will allow us to make a direct comparison of blood pressure in
mice containing different allelic variants. Once these gene-tar-
geted transgenics are generated, we will make use of preexist-
ing HREN transgenics and mAgt-deficient mice as described
in this report to test the functional significance of genetic vari-
ants of the HAGT gene.
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